ARPA-H Backs 3 Osteoarthritis Regeneration Projects With Up to $33 Million, Demanding Human Trials in 18 Months
Updated
Updated · Futura · May 24
ARPA-H Backs 3 Osteoarthritis Regeneration Projects With Up to $33 Million, Demanding Human Trials in 18 Months
1 articles · Updated · Futura · May 24
Three ARPA-H-backed teams at Duke, Colorado Boulder and Columbia won tissue-regeneration support for osteoarthritis, with Duke alone eligible for up to $33 million and all projects now racing toward human testing.
Within 18 months of the April award, each team must launch clinical trials despite results so far being limited to animals, where arthritis therapies have often failed to translate to humans.
Duke is developing annual injectable and intravenous small-molecule treatments, Colorado Boulder built joint-injected particles that release a repurposed drug over months, and Columbia is pursuing a living 3D-printed knee grown on a biodegradable scaffold.
Federal contracts also require that more than half of trial participants be women, that Native American and Alaska Native patients be actively recruited, and that any approved therapy cost no more than one-quarter of current standard treatments.
The push targets a disease that costs the U.S. healthcare system about $128 billion a year and still lacks a cure, making successful bone and cartilage regrowth a potential overhaul of orthopedic care.
With a new push for deregulation, can patient safety be guaranteed for these experimental living joint therapies?
Can revolutionary joint cures succeed commercially if their price is capped at a fraction of current treatments?
If a 3D-printed knee is grown from your cells, who truly owns and controls this living part of your body?
From Palliative Care to Regeneration: How ARPA-H’s NITRO Program Aims to Transform Osteoarthritis Treatment for Millions
Overview
The Advanced Research Projects Agency for Health (ARPA-H) has launched the NITRO program to transform osteoarthritis (OA) treatment by enabling the body to regenerate damaged joint tissues, moving beyond current palliative care and artificial joint replacements. With a focus on accelerating better health outcomes for all Americans, especially those historically overlooked in clinical research, NITRO supports teams preparing for first-in-human clinical trials. These trials, led by UCLA Health, will follow rigorous safety and regulatory steps required by the FDA. The program marks a bold step toward innovative, regenerative therapies that could reshape the future of OA care.